Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
Go back to Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs| (NASDAQ: SANA) | Delayed: 2.68 -0.09 (3.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.77 | 52 Week High | $ | |||
| Open | $2.77 | 52 Week Low | $ | |||
| Day High | $2.85 | P/E | N/A | |||
| Day Low | $2.67 | EPS | $ | |||
| Volume | 2,254,677 | |||||
